Light Therapy for Psoriasis Patients

Article

The healthcare technology company Philips has launched BlueControl 2.0, a device created to treat patients afflicted with psoriasis.

The healthcare technology company Philips has launched BlueControl 2.0, a device created to treat patients afflicted with psoriasis.

Psoriasis patients deal with immune systems triggered to cause rapid skin cell growth, which leads to the “excessive multiplication and improper differentiation (hyperproliferation) of a certain type of skin cell known as keratinocytes.”

As such, the blue LEDS — when shone on the keratinocytes – work to reduce the number of keratinocytes thereby increasing their differentiation.

The company collaborated with the Dermatology Department at the University Hospital Aachen, Germany, and discovered that one the psoriasis patients were exposed to the blue LEDs, “a significant improvement of the symptoms could be observed due to treatment of the affected skin area”.

This knowledge led to the inception of BlueControl in 2014, “the world’s first wearable blue LED light therapy device to treat skin disease psoriasis vulgaris”. The device’s successor, BlueControl 2.0 includes 40 LED lights, is easily strapped on to the body, and has more than enough battery life to last four treatments prior to recharging.

Related Videos
What Makes JAK Inhibitors Safe in Dermatology
Potential JAK Inhibitor Combination Regimens in Dermatology
Therapies in Development for Hidradenitis Suppurativa
"Prednisone without Side Effects": The JAK Inhibitor Ceiling in Dermatology
Discussing Changes to Atopic Dermatitis Guidelines, with Robert Sidbury, MD, MPH
How Will Upadacitinib, Povorcitinib Benefit Hidradenitis Suppurativa?
The JAK Inhibitor Safety Conversation
Jonathan Silverberg, MD, PhD, MPH | Credit: George Washington University
Secukinumab and Bimekizumab for Hidradenitis Suppurativa
Mona SHahriari, MD | Credit: Central Connecticut Dermatology
© 2024 MJH Life Sciences

All rights reserved.